TickerFacts.

Viemed Healthcare, Inc. (VMD): R&D Expense

Annual figures by period end, from SEC filings.

$3.02M
Year ended 2025-12-31
$2.46M
Trailing 12 months to 2026-06-30
+3.8%
3-year compound annual growth
+22.7%
5-year compound annual growth
$3.07M2018-12-31: $02019-12-31: $848.0K2020-12-31: $1.08M2021-12-31: $2.11M2022-12-31: $2.70M2023-12-31: $2.78M2024-12-31: $3.07M2025-12-31: $3.02M$3.02M
2018-12-31 R&D Expense (USD) 2025-12-31
Period endedR&D ExpenseChange YoYSource filing
2025-12-31$3.02M-1.7%2026-03-04, From 2025-01-01
2024-12-31$3.07M+10.3%2026-03-04, From 2024-01-01
2023-12-31$2.78M+3.2%2026-03-04, From 2023-01-01
2022-12-31$2.70M+27.8%2025-03-10, From 2022-01-01
2021-12-31$2.11M+94.8%2023-03-02, From 2021-01-01
2020-12-31$1.08M+27.7%2022-03-07, From 2020-01-01
2019-12-31$848.0Kn/a2021-03-03, From 2019-01-01
2018-12-31$0n/a2020-03-04, From 2018-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Services-Misc Health & Allied Services, NEC), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
Viemed Healthcare, Inc. (VMD)2025-12-31$3.02M-1.7%
Progyny, Inc. (PGNY)2025-12-31$9.50Mn/a
Cryo Cell International Inc (CCEL)2025-11-30$376.3K-69.7%
Marpai, Inc. (MRAI)2025-12-31$7.0K-75.9%
BioRestorative Therapies, Inc. (BRTX)2025-12-31$10.09M+50.5%

Compare VMD, PGNY, CCEL, MRAI side by side · Screen every company in Services-Misc Health & Allied Services, NEC ↗